Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 19/20 | 0.60 |
| ▸ | GPR174 | Q9BXC1 | 13/20 | 0.60 |
| ▸ | GPR34 | Q9UPC5 | 9/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13976386 | 0.84 | P2RY10 (0.64) | P2RY10GPR174GPR34 | |
| SCHEMBL19347656 | 0.84 | P2RY10 (0.50) | P2RY10GPR174GPR34 | |
| SCHEMBL30244695 | 0.83 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL13863415 | 0.83 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL22219423 | 0.83 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL2017576 | 0.83 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL29715574 | 0.83 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL21067706 | 0.83 | P2RY10 (0.56) | P2RY10GPR174GPR34 | |
| SCHEMBL26642832 | 0.82 | P2RY10 (0.84) | P2RY10GPR174GPR34 | |
| SCHEMBL9910884 | 0.81 | P2RY10 (0.49) | P2RY10GPR174GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281065-A1 | Use of Lysophospholipids to Treat Inflammation | KEMIN INDUSTRIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281065-A1 | Use of Lysophospholipids to Treat Inflammation | LPCAT1, LPCAT3, LYPLAL1 | P2RY10 716/4885GPR174 1186/4885GPR34 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.